A prospective study on the prevalence of <scp>MASLD</scp> in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies

Abstract

Screening for MASLD in the diabetic population in primary care is cost-effective and should become part of a holistic assessment. However, traditional screening strategies, including FIB-4 and ELF, underestimate the presence of significant liver disease in this setting.